Xtacy Therapeutics Corp. Share Price Deutsche Boerse AG
Equities
TT5
CA98423G1072
Investment Management & Fund Operators
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.011 EUR | 0.00% | -43.59% | -12.00% |
Sales 2022 | - | Sales 2023 | - | Capitalization | 2.46M 2.29M 205M |
---|---|---|---|---|---|
Net income 2022 | -1M -929K -83.48M | Net income 2023 | - 0 0 | EV / Sales 2022 | - |
Net Debt 2022 | 25.37K 23.56K 2.12M | Net Debt 2023 | 16.7K 15.51K 1.39M | EV / Sales 2023 | - |
P/E ratio 2022 |
-3.97
x | P/E ratio 2023 |
-4.19
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 89.2% |
1 week | -43.59% | ||
Current month | -15.38% | ||
1 month | -31.25% | ||
3 months | -53.19% | ||
6 months | -12.00% | ||
Current year | -12.00% |
Managers | Title | Age | Since |
---|---|---|---|
Meris Kott
CEO | Chief Executive Officer | - | 30/17/30 |
Lindsey R. Perry
DFI | Director of Finance/CFO | 70 | 10/19/10 |
Monita Faris
SEC | Corporate Secretary | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Lindsey R. Perry
DFI | Director of Finance/CFO | 70 | 10/19/10 |
Meris Kott
CEO | Chief Executive Officer | - | 30/17/30 |
Ashleigh Vogstad
BRD | Director/Board Member | - | 30/19/30 |
Date | Price | Change |
---|---|---|
10/24/10 | 0.011 | 0.00% |
09/24/09 | 0.011 | +4.76% |
08/24/08 | 0.0105 | -27.59% |
07/24/07 | 0.0145 | -27.50% |
06/24/06 | 0.02 | +2.56% |
Delayed Quote Deutsche Boerse AG, May 10, 2024 at 11:34 am IST
More quotes1st Jan change | Capi. | |
---|---|---|
-1.86% | 118B | |
+3.26% | 95.3B | |
+13.75% | 69.05B | |
+20.25% | 63.76B | |
+12.28% | 43.7B | |
+14.14% | 43.06B | |
+17.76% | 34.41B | |
+3.63% | 24.92B | |
-1.14% | 23.07B |
- Stock Market
- Equities
- XTCY Stock
- TT5 Stock